The Quantellect read.As of Nov 19, 2026, 3 active firms cover Tscan Therapeutics Inc: 0 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $1.00 to $6.00 (about 6.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $2.67 sits 1740% above the current $0.14. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.20 next quarter toward $-0.71 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy00%
Neutral3100%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$2.67
+1740.3% upside
Average target across 3 active firms as of Nov 19, 2026 vs $0.14 current
Highest Target$6.00
Average Target$2.67
Lowest Target$1.00
Detailed analyst forecasts for TCRX
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 0 of 3 active firms rate TCRX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TCRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.26 – $-0.13 · 2 analysts · -11% YoY
Next period, 2 analysts expect Tscan Therapeutics Inc to earn $-0.20 a share (range $-0.26 – $-0.13), versus $-0.22 a year earlier. Full-year consensus is $-0.83, growing to $-0.71 the year after.
REVENUE · NEXT QUARTER
$433.3K
Range $0 – $1.3M · 2 analysts · -56% YoY
Revenue is expected to reach $433.3K (range $0 – $1.3M), -55.9% year-over-year. Full-year consensus is $2.6M, rising to $1.7M next year.
Top analysts covering Tscan Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TCRX.
#1
David Nierengarten
Wedbush · Rank #24
Neutral
$1.00+590.1% to target
Overall win rate
48%
+ Follow
#2
Peter Lawson
Barclays · Rank #89
Buy
$3.00+1970.4% to target
Overall win rate
45%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Neutral
$1.00+590.1% to target
Overall win rate
39%
+ Follow
#4
Gil Blum
Needham · Rank #409
Neutral
No targeton TCRX
Overall win rate
27%
+ Follow
#5
Justin Zelin
BTIG · Rank #495
Neutral
No targeton TCRX
Overall win rate
30%
+ Follow
TCRX stock forecast FAQ
What is TCRX's average 12-month price target?+
The 3 active firms with a live target average $2.67 for Tscan Therapeutics Inc over the next 12 months, ranging from a $6.00 high to a $1.00 low, as of Nov 19, 2026.
Is TCRX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TCRX?+
The Street-high target is $6.00, and the Street-low is $1.00 (HC Wainwright & Co.). The average of all 3 active-firm targets is $2.67.
How many active Wall Street firms cover TCRX?+
3 active firms have a recognized rating on Tscan Therapeutics Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TCRX?+
Among analysts who currently cover TCRX, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Neutral with a $1.00 target.
What is Tscan Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.26 – $-0.13) across 2 analysts. Full-year EPS is projected at $-0.83, rising to $-0.71 the following year.
How much revenue is Tscan Therapeutics Inc expected to report next quarter?+
Consensus revenue is $433.3K (range $0 – $1.3M). Full-year revenue is projected at $2.6M, growing to $1.7M next year.
Have analysts been upgrading or downgrading TCRX lately?+
As of Nov 19, 2026, 0 of 3 active firms rate TCRX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.